Xuanzhu Biopharm, an innovative drug research and development company, recently has completed its Series A round of financing, raising 800 million yuan from SDIC.
This round of financing will be used to support Xuanzhu Biopharm in its R&D of the innovative drugs, and to promote the establishment of marketized clinical R&D platforms.
Established in 2002 with a registered capital of 100 million yuan, Xuanzhu Biopharm is a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group and an innovative drug research institute.
It is mainly engaged in the research and development of the NMEs, and its research fields involve the cutting-edge R&D fields of anti-infection, anti-cardiovascular and metabolic diseases, and anti-tumor.
Xuanzhu Biopharm produces various kinds of drugs that are used for different diseases including cancer, diabetes, metabolic diseases, digestive system diseases, andrology-related diseases, and infections. Many of these drugs have entered the late clinical phase.